Introduction {#s1}
============

Recent statistical studies concerning the incidence of malignancies propose that despite the clinical success obtained during the previous years, cancer is expected to be the leading cause barrier of increasing life expectancy in the 21st century ([@B1], [@B2]). This is, at least partially, attributed to the fact that cancer therapies are still applied on an experience-based manner and often without taking into consideration the special genomic and proteomic landscape of the tumor. Consequently, cancer therapy still fails to provide long-lasting outcomes, while many regimens are often toxic and costly for patients and healthcare systems. Personalized medicine in oncology strives to overcome those limitations by integrating genomic, transcriptomic, and proteomic analysis of tumor samples to decision-making in oncology. In a typical screening of such type, multiple genes and proteins implicated in tumor initiation, progression, and drug resistance are analyzed in tumor biopsies in order to identify potential alterations that may aid in therapy decision. The success of the technology has already been demonstrated for various combinations of altered biomarkers and therapeutic molecules, such as epidermal growth factor receptor (EGFR) expression and EGFR tyrosine kinase inhibitors/antibodies, or the expression of programmed death ligand 1 (PD-L1) with anti-PD1 and anti-PD-L1 therapies. This way, clinicians obtain a personalized therapeutic overview, which assists them to decide on the potential: (a) clinical benefit, (b) inefficacy, and (c) toxicity of a treatment. Moreover, they are informed on the potential utility of a drug with an off-label indication or about treatments that are under investigation in ongoing clinical trials.

Multiple studies have provided solid proof on the significance of molecular tumor profiling in precision cancer therapy. Initial efforts in the field have focused on tumor genomic profiling, based solely on Next-Generation Sequencing (NGS) technology, to show that such analysis may enable improved therapeutic outcomes ([@B3], [@B4]). Evidently, NGS analysis has resulted in the identification of a plethora of actionable variants that influence drug safety and efficacy in the clinical setting. Nowadays, ongoing studies and clinical trials include tissue genomic and transcriptomic analysis ([@B5]), while others also include immunohistochemistry, tumor mutational burden (TMB), and microsatellite instability (MSI) ([@B6]). Moreover, high-throughput methods in the fields of transcriptomics and proteomics are constantly being developed in parallel with sophisticated data analysis software tools. To date, all studies conclude that the molecular tumor profiling represents the best approach for obtaining information that would be useful to clinicians in routine oncology practice. The final goal would be to implement complex strategies of molecular profiling and guide the proper treatment approach for each patient independently in a cost-effective manner ([@B7]--[@B10]).

Despite the recent advances in profiling technology and the accumulating knowledge in the field of pharmacogenomics, personalized treatment care is still often missing especially in small oncology practices and centers. Toward this direction, the implementation of precision cancer medicine in routine private healthcare is presented in this work. The data analysis of 17 consented cancer patients are included, whom tumor biopsy samples were subjected to molecular profiling analysis to guide personalized therapy interventions. All patients provided a primary tumor sample for molecular analysis, after failing at least one standard of care treatment. By carefully monitoring each patient\'s response, we recorded patient cancer status before and after the initiation of the pharmacogenomics-based therapy. We report that the application of a personalized therapy, based on tumor profiling, favorably impacted response to therapy in 8 out of the 17 patients. We, also, describe the example of a patient with Stage IV metastatic gastric adenocarcinoma who demonstrated a complete response (CR) to an off-label molecularly targeted therapy and continued maintenance therapy with the proposed therapy while currently maintaining his CR status.

Patients and Methods {#s2}
====================

A written informed consent was obtained from all the patients included in the present study (no minors exist within this group). In particular, the progression of 17 patients diagnosed with various types of cancer and consented to provide an excised primary tumor sample for molecular analysis, after failing at least one standard of care treatment, was monitored and reported. All types of molecular analysis on the patient tissue samples were conducted between March 2017 and November 2018 by applying the OncoDEEP™ (OncoDNA SA, Gosselies, Belgium) profiling solutions. The methodology applied in precision medicine strategy upon the patient sample handling, the DNA isolation, the NGS, the interpretation of the generated data, the identification of putative somatic mutations, as well as the analysis of immunohistochemistry (IHC) results, along with the clinical translation and implementation of the molecular data to the oncologist\'s evaluation report, has been previously described in detail ([@B8]). Importantly, all patients were informed about the OncoDEEP™ solutions and the suggested therapy by the medical oncologist and they consented before the tumor tissue sample was taken and sent for the molecular testing. The average age of the patients during their diagnosis was 52 years; 11 (\~65%) of them were men and 6 (\~35%) were women. The cancer types and the treatment schemes applied to patients based on routine clinical practice and after the OncoDEEP™ molecular profiling is presented in detail in [Table 1](#T1){ref-type="table"}.

###### 

Patient information concerning personal information, malignancy type, and treatments received.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Code**   **Diagnosed cancer type**           **Age (range[^\*^](#TN1){ref-type="table-fn"}) upon diagnosis**   **Therapeutic scheme**                                     
  ---------- ----------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------
  CYP100     Colorectal cancer                   60--70                                                            \(a\) Xelox\                                               \(c\) FOLFIRI and Bevacizumab
                                                                                                                   (b) FOLFOX                                                 

  CYP101     Ovarian cancer                      40--50                                                            \(a\) Carboplatin and Paclitaxel\                          \(f\) Caeloyx
                                                                                                                   (b) Caelyx and Carboplatin\                                
                                                                                                                   (c) Carboplatin and Gemcitabine\                           
                                                                                                                   (d) Topotecan\                                             
                                                                                                                   (e) Docetaxel                                              

  CYP102     Gastric cancer                      40--50                                                            \(a\) Xelox                                                \(b\) EOX\
                                                                                                                                                                              (c) Pembrolizumab

  CYP103     Carcinoma of unknown primary site   50--60                                                            \(a\) Cisplatin and Capecitabine                           \(b\) ECX\
                                                                                                                                                                              (c) Nivolumab\
                                                                                                                                                                              (d) Gemcitabine and Taxol

  CYP104     Small cell lung cancer              70--80                                                            \(a\) Cisplatin, Etoposide and Zometa\                     \(c\) Topotecan weekly and Zometa
                                                                                                                   (b) Paclitaxel and Zometa                                  

  CYP105     Cervix adenocarcinoma               20--30                                                            \(a\) Cisplatin and Etoposide\                             \(d\) Carboplatin, Paclitaxel and Bevacizumab\
                                                                                                                   (b) Radiotherapy/chemotherapy\                             (e) CAV
                                                                                                                   (c) Paclitaxel/Topotecan                                   

  CYP106     Cholangiocarcinoma                  60--70                                                                                                                       \(a\) Gemcitabine and Cisplatin\
                                                                                                                                                                              (b) FOLFOX

  CYP107     Pancreatic cancer                   60--70                                                            \(a\) FOLFIRINOX\                                          
                                                                                                                   (b) Gemcitabine and Abraxane\                              
                                                                                                                   (c) Gemcitabine and Abraxane                               

  CYP108     Non-Small Cell Lung Cancer          60--70                                                            \(a\) Cisplatin and Pemetrexed\                            
                                                                                                                   (b) Pemetrexed maintenance\                                
                                                                                                                   (c) Carboplatin/Paclitaxel/ Bevacizumab\                   
                                                                                                                   (d) Nivolumab (Opdivo)                                     

  CYP109     Sarcoma                             40--50                                                            \(a\) Crizotinib (oral)                                    \(b\) Alectinib (oral)\
                                                                                                                                                                              (c) Alectinib and Pembrolizumab

  CYP110     Melanoma                            30--40                                                            \(a\) Ipilimumab\                                          \(e\) TIL Adoptive cell therapy\
                                                                                                                   (b) Pembrolizumab and Ipilimumab and Zometa x\             (f) Pembrolizumab and Zometa\
                                                                                                                   (c) Nivolumab and Ipilimumab and Zometa\                   (g) Carboplatin, Paclitaxel and Pembrolizumab
                                                                                                                   (d) Pembrolizumab and Ipilimumab and Zometa                

  CYP111     Cholangiocarcinoma                  60--70                                                            \(a\) Gemcitabine and Cisplatin                            

  CYP112     Pancreatic cancer                   40--50                                                            \(a\) Gemcitabine and Abraxane (Nab-paclitaxel)            \(b\) Re-challenge Gemcitabine and Abraxane

  CYP113     Thymoma and Thymic carcinoma        30--40                                                            \(a\) Cyclophosphamide, Doxorubicin and Cisplatin (CAP)\   \(h\) Carboplatin, Paclitaxel and Bevacizumab
                                                                                                                   (b) Brachytherapy\                                         
                                                                                                                   (c) CAP\                                                   
                                                                                                                   (d) CAP\                                                   
                                                                                                                   (e) Brachytherapy\                                         
                                                                                                                   (f) Radiotherapy\                                          
                                                                                                                   (g) Carboplatin and Etoposide                              

  CYP114     Triple-negative breast cancer       50--60                                                            \(a\) TDM1, Gemcitabine and Carboplatin                    \(b\) TDM1, Paclitaxel and Carboplatin\
                                                                                                                                                                              (c) Heceptin, Paclitaxel and Zometa\
                                                                                                                                                                              (d) Capecitabin, Vinorelbine and Zometa

  CYP115     Leiomyosarcoma                      50--60                                                            \(a\) Lartruvo and Doxorubicin\                            \(b\) Gemcitabine and Docetaxel
                                                                                                                   (c) Brachytherpay                                          

  CYP116     Cholangiocarcinoma                  60--70                                                                                                                       \(a\) Gemcitabine and Cisplatin × 6 cycles\
                                                                                                                                                                              (b) Gemcitabine maintenance × 2 cycles\
                                                                                                                                                                              (c) CAP-OX (Capecitabine and Oxaliplatin
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Age is shown as decade range for ensuring patient privacy*.

Moreover, we used Resist Criteria 1.1 for assessment and evaluation of therapy response (also called Response Evaluation Criteria In Solid Tumors). The types of response a patient can have are a complete response (CR), a partial response (PR), progressive disease (PD), and stable disease (SD). According to the guidelines, the scores are explained as follows: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Moreover, we used the term Mixed Response (MR), which denotes that a tumor group located in a certain anatomical site responded to treatment but a different group in another anatomical site did not respond, reflecting the heterogeneity of tumors and differential response in different organs.

Results {#s3}
=======

Analysis of the Mutations Identified in the Patient Samples
-----------------------------------------------------------

Investigation of the genomic landscape of a tumor through NGS analysis allows the identification of actionable variants that promote tumor initiation and progression. Accumulating research over the past decade led to the clinical validation of multiple variants as pharmacogenomic biomarkers. With OncoDEEP™, each patient sample was screened for mutations in 65 genes that have evidently been related to cancer. At least one mutation was identified in 14 out of the 17 patients analyzed; 2 patients had no mutations (within the panel of the genes tested by NGS analysis) while the analysis failed for 1 patient due to bad sampling. In total, 25 unique mutations were identified in the group of patients, with Rat (RAS) sarcoma isoforms (6 mutations) and the tumor protein p53 (TP53, 4 mutations) being the most frequently mutated genes ([Table 2](#T2){ref-type="table"}; [Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). Additionally, 21 out of the 25 (84%) mutations were classified as damaging, denoting that these variants had a known functional impact (activating or inhibiting) on the protein encoded, and this is supported by both research and clinical information. The rest of the variants (4 out of 25, 16%) were classified as potentially damaging, thus denoting that for those variants, there may be *in vitro* information but no clinical data supporting a role in altering protein function. As for the mutational burden of the tumor, most patients demonstrated a single or no mutation (11 out of 16), whereas 3 patients had between 2 and 3 mutations. Conversely, a patient with small-cell lung cancer demonstrated the highest number of mutations identified in a single tumor with five mutations presenting in key genes driving tumor progression (PIK3CA, JAK3, TP53, FGFR4, and JAK2). An overview of the mutated genes and the total number of patients bearing each mutation are shown in [Table 2](#T2){ref-type="table"}.

###### 

Total number of mutations identified in the patients\' cancer genome.

  --------------------------------------------------------------------------------------------------------------------------------------------
  **Mutated gene**   **Number of patients with mutation**   **Mutation type**\                                           **Patient code**
                                                            $\mathbf{\text{(red:\ damaging\ mutations;}}$\               
                                                            $\mathbf{\text{blue:\ potentially\ damaging\ mutations)}}$   
  ------------------ -------------------------------------- ------------------------------------------------------------ ---------------------
  RAS                6                                      $\text{c35G>A}$\                                             CY100\
                                                            $\text{c.181C>A}$\                                           CY102\
                                                            $\text{c.34G>C}$\                                            CY103\
                                                            $\text{c.35G>T}$                                             CY106, CY107, CY112

  TP53               4                                      $\text{c.818G>A}$\                                           CY101\
                                                            $\text{c.202G>T}$\                                           CY108\
                                                            $\text{c.586C>T}$\                                           CY112\
                                                            $\text{c.504del}$                                            CY114

  PIK3CA             3                                      $\text{c.263G>A}$\                                           CY102\
                                                            $\text{c.1636C>A}$\                                          CY108\
                                                            $\text{c.3140A>G}$                                           CY114

  TPMT               2                                      $\text{c.719A>G}$\                                           CY103\
                                                            $\text{c.460G>A}$                                            CY112

  RB1                1                                      $\text{c.2148\_2156del}$                                     CY104

  GNAS               1                                      $\text{c.2531G>A}$                                           CY105

  CDKN2A             1                                      $\text{c.210\_211insC}$                                      CY106

  JAK3               1                                      $\text{c.2164G>A}$                                           CY108

  JAK2               1                                      $\text{c.1666T>G}$                                           CY108

  FGFR4              1                                      $\text{c.2018G>A}$                                           CY108

  SMO                1                                      $\text{Genomic\ amplification}$                              CY110

  AKT1               1                                      $\text{c.49G>A}$                                             CY114

  SMAD4              1                                      $\text{c.346C>T}$                                            CY114

  PMS2               1                                      $\text{c.1866G>A}$                                           CY116
  --------------------------------------------------------------------------------------------------------------------------------------------

The generated NGS data and the variants identified were used in order to advice on a potential therapy for the patients. For instance, mutations in the KRAS oncogene locus relate with resistance to an anti-epidermal growth factor receptor (anti-EGFR) therapy, thereby connecting such a treatment with poor clinical benefit and, thereby, the oncologist was discouraged from choosing it ([@B11], [@B12]). Similarly, a damaging thiopurine methyltransferase (TPMT) variant was used in order to exclude a cisplatin therapy in a patient with pancreatic cancer, as reduced metabolism of the drug due to the variant would lead to enhanced toxicity for that patient. Finally, the NGS analysis identified genomic amplification of the smoothened homolog (SMO) gene in a melanoma patient and thereby SMO inhibitors (sonidegib and vismodegib) were suggested as a treatment of choice for that cancer ([@B13]). The described examples underline the importance of investigating the genomic landscape of cancer before deciding on a proposed therapy.

Molecular Analysis of Protein Pharmacogenomic Biomarkers
--------------------------------------------------------

Similar to genetic biomarkers, the analysis of common biomarkers of proteinaceous nature is highly informative in personalized cancer therapy. Examples of such biomarkers include the elevated expression of Topoisomerase I and 4E-Binding protein (p4E-BP1), which relate to a beneficial response to Topoisomerase 1 inhibitors and PI3K/mTOR inhibitors, respectively ([@B14], [@B15]). On the contrary, multiple studies suggest that increased expression of the excision repair complementation group 1 (ERCC1) protein induces resistance to platinum-based chemotherapy ([@B16]--[@B18]). In total, the expression and the presence of multiple proteins and biomarkers that have evidently been connected to response to a particular therapy were analyzed (all biomarkers are shown in detail in [Supplementary Figures 2](#SM1){ref-type="supplementary-material"}, [3](#SM1){ref-type="supplementary-material"}). Notably, at the protein level, p4E-BP1 and ERCC1 were found to be frequently upregulated ([Supplementary Figure 2](#SM1){ref-type="supplementary-material"}). These findings suggest that those patients may receive mammalian target of rapamycin (mTOR) inhibitors, but they should avoid a platinum-based chemotherapy due to ERCC1 overactivation, which would undermine the therapeutic outcome. Moreover, multiple patients demonstrated high expression of the cluster of differentiation 8 (CD8) protein, thus suggesting that a therapy with anti-CD8 (checkpoint) inhibitors would be a beneficial regimen. In total, the data generated from known protein biomarkers constituted a common strategy to choose a potential therapy in the group of 17 patients.

Clinical Response of Patients Receiving Personalized Treatment Based on the Tumor Genome Molecular Analysis
-----------------------------------------------------------------------------------------------------------

The outcome of the OncoDEEP™ analysis is a report that includes a list of therapies associated with (a) clinical benefit, (b) potential lack of benefit, or (c) toxicity. To evaluate the outcome of the suggested therapy for the group of 17 patients, we monitored how each patient responded to the applied therapy. For that, we used Resist Criteria 1.1 to classify the therapeutic outcome into the following: Complete Response (CR), Partial Response (PR), Mixed Response (MR), Progressive Disease (PD), and Stable Disease (SD); criteria are explained in detail under the Patients and methods section). Interestingly, we report that 8 out of the 17 patients (47%) showed an overall positive response to the molecularly guided therapy. The detailed response records for these eight patients are shown in [Figure 1](#F1){ref-type="fig"}. Therapy regimens given before the personalized assessment are shown in red, whereas the personalized treatment is highlighted with blue. Moreover, we observe that the earlier a molecularly guided therapy is applied, the more beneficial the therapeutic outcome was. This is evident when comparing the treatment responses between the groups of CY114--CY102--CY115 to that of CY113--CY115. In particular, patient CY113 failed to respond to seven rounds of anti-cancer therapies, before receiving a pharmacogenomic-based therapy with a positive outcome. Concerning the entire group, we observe that most patients responded positively to the treatment, with 5 out of 17 (29%) demonstrating partial response, 1 patient demonstrating mixed response, and 1 patient showing CR to the treatment suggested ([Figure 2](#F2){ref-type="fig"}). On the other hand, 4 out of 17 (23,5%) patients remained stable and another 4 out of 17 developed a progressive disease (23,5%). The responses for the suggested treatments for all patients are shown in [Figure 2](#F2){ref-type="fig"}.

![Treatment record for the eight patients that showed positive response to the suggested treatment. The *x*-axis displays a timeline (per 6 months), while the *y*-axis shows the response of the patient before applying the displayed treatment. Therapy regimens given before the personalized assessment are shown in red, whereas the personalized treatment is highlighted with blue. Plots were created using the ggplot2.](fonc-10-00521-g0001){#F1}

![Data analysis showing the clinical response to the personalized treatment for all patients included in this study.](fonc-10-00521-g0002){#F2}

Case Study
----------

As a case study, we report the example of a patient with Stage IV metastatic gastric adenocarcinoma with nodal and liver metastases that responded completely to the treatment (CY102, first patient in [Figure 1](#F1){ref-type="fig"}, age range 40--50). Following the cancer diagnosis at 07/2016, the patient\'s samples were sent for molecular analysis at 10/2016. Based on the data obtained, this patient had a positive expression of topoisomerase 1 (TOPO1) and TOPO2A proteins. For that reason, a topoisomerase I or topoisomerase II inhibitor was highly suggested as a beneficial therapeutic regimen. Moreover, cancer cells demonstrated high expression of Programmed death-ligand 1 (PD-L1), thus denoting that a PD-1/PD-L1 inhibitor therapy would likely be associated with a positive response. Indeed, epirubicin (topoisomerase II inhibitor) was added to the therapeutic regimen in a 3-cycle EOX (epirubicin, oxaliplatin, capecitabine) chemotherapy scheme. Afterward, pembrolizumab, an anti-PD1/PD-L1 immunotherapy, was initiated with CR after the first CT re-evaluation scan. The patient had very little treatment toxicities, and thus, he started on maintenance treatment with pembrolizumab and is currently continuing maintenance therapy on a 3-weekly basis. He is currently well with a performance status of 0 and a recent PET/CT scan did not reveal any local or distance disease recurrence. By delivering this pharmacogenomics-based therapeutic strategy, the oncology team was capable of noticing that there were other treatment options that, at the time, were not recommended by any International Guidelines, but were suggested by the report, and thus, by the initiation of the suggested medication, resulted in a CR with the patient to be now in cancer-free maintenance status.

Discussion
----------

Providing effective and long-lasting therapeutic outcomes in clinical oncology remains a pressing medical problem worldwide. The inherent complexity of the cancer cell physiology, the tumor microenvironment, as well as the inter-individual differences are variables that highly impact therapy progression. Despite the substantial technological advances in the omics and data analysis fields, information by tumor profiling is still rarely utilized by clinicians when deciding on a potential therapy. Multiple reasons, including availability to the test, lack of information, as well cost, are still considered barriers for the implementation of the technology in the routine clinical practice ([@B19]).

Nevertheless, most studies in the field conclude that, indeed, tumor profiling represents the best approach for obtaining information that would be useful to clinicians in the routine oncology practice. While initial studies focused mainly on genomic profiling, nowadays, studies and tests include transcriptomic, proteomic, and other biomarker testing such microsatellite instability (MSI) and immunograms. Moreover, expert-guided precision oncology bases are constantly being developed, in order to connect tumor-related mutations with standardized pharmacogenomic reports (such as the OncoKB) ([@B20]) or to simulate pharmacokinetic and pharmacodynamic effects of therapeutics in the body ([@B21]). The end products of this research are commercially available tests, such as the OncoDEEP™, which offers a comprehensive combination of DNA, RNA, and protein tests, followed by data analysis and data interpretation to provide easily interpretable knowledge on a personalized manner. By that, clinicians can best decide on chemotherapy, targeted therapy, or immunotherapy, and deliver more effective, safe, and less costly therapies.

The data presented in this study further highlight the importance of molecularly guided therapeutic decisions in the clinical setting. All patient management was conducted in a private oncology center; hence, our study represents a paradigm on how molecular tumor profiling can be broadly implemented by clinicians working in small centers, worldwide. The analysis suggests that tumor profiling can improve overall disease response rates. Moreover, despite the fact that the study was conducted on a small number of patients, we observe that the earlier a pharmacogenomic-based therapy is initiated, the better and more durable the therapeutic outcome is. A limitation of this analysis is, indeed, it is relatively small scale, including only 17 patients. Nevertheless, our goal was to exactly demonstrate how tumor profiling information can provide quick and durable solutions in oncology decision-making in small- to medium-sized centers. Moreover, our case study shows how a drug that was not recommended by any International Guideline can be repurposed to target a highly aggressive type of cancer in a unique patient. This is a typical example of how personalized medicine can provide therapeutic solutions that would otherwise be neglected. In conclusion, we expect that this work will urge healthcare professionals to more broadly implement tumor profiling in their everyday clinical practice.
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